TITLE

Use of proton pump inhibitors and risk of osteoporosis-related fractures

AUTHOR(S)
Targownik, Laura E.; Lix, Lisa M.; Metge, Colleen J.; Prior, Heather J.; Leung, Stella; Leslie, William D.
PUB. DATE
August 2008
SOURCE
CMAJ: Canadian Medical Association Journal;8/12/2008, Vol. 179 Issue 4, p319
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: The use of proton pump inhibitors has been associated with an increased risk of hip fracture. We sought to further explore the relation between duration of exposure to proton pump inhibitors and osteoporosis-related fractures. Methods: We used administrative claims data to identify patients with a fracture of the hip, vertebra or wrist between April 1996 and March 2004. Cases were each matched with 3 controls based on age, sex and comorbidities. We calculated adjusted odds ratios (OR) for the risk of hip fracture and all osteoporosis-related fractures for durations of proton pump inhibitor exposure ranging from 1 or more years to more than 7 years. Results: We matched 15 792 cases of osteoporosis-related fractures with 47 289 controls. We did not detect a significant association between the overall risk of an osteoportic fracture and the use of proton pump inhibitors for durations of 6 years or less. However, exposure of 7 or more years was associated with increased risk of an osteoporosisrelated fracture (adjusted OR 1.92, 95% confidence interval [CI] 1.16-3.18, p = 0.011). We also found an increased risk of hip fracture after 5 or more years of exposure (adjusted OR 1.62, 95% CI 1.02-2.58, p = 0.04), with even higher risk after 7 or more years exposure (adjusted OR 4.55, 95% CI 1.68-12.29, p = 0.002). Interpretation: Use of proton pump inhibitors for 7 or more years is associated with a significantly increased risk of an osteoporosis-related fracture. There is an increased risk of hip fracture after 5 or more years exposure. Further study is required to determine the clinical importance of this finding and to determine the value of osteoprotective medications for patients with long-term use of proton pump inhibitors.
ACCESSION #
33461971

 

Related Articles

  • Clinical briefs.  // New Zealand Doctor;9/24/2008, p23 

    This section offers medical news briefs. U.S. researchers have successfully grown blood types A, B, O and Rh-positive and Rh-negative blood from human embryonic cells. A Finnish research suggests that the use of steroids for children could be reduced as soon as their asthma has been controlled....

  • A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate. Lee, Joongyub; Youn, KyungEun; Choi, Nam-Kyong; Lee, Jin-Ho; Kang, DongYoon; Song, Hong-Ji; Park, Byung-Joo // Journal of Gastroenterology;Sep2013, Vol. 48 Issue 9, p1016 

    Background: Studies on the risk of osteoporotic fractures related to the use of proton pump inhibitors (PPIs) have been inconsistent. One recent cohort study reported that there was an interaction between PPIs and bisphosphonates (BPs). Thus we performed a case-control study aimed at evaluating...

  • PPIs linked to osteoporosis.  // Practice Nurse;1/12/2007, Vol. 33 Issue 1, p6 

    The article reports that long-term use of proton pump inhibitors (PPI) for the treatment of stomach acid problems may increase the risk of hip fracture. Researchers from the University of Pennsylvania School of Medicine found that patients taking PPI for more than a year had a 44% greater risk...

  • Long-term use of proton pump inhibitors increased bone fracture risk.  // Endocrine Today;10/25/2008, Vol. 6 Issue 19, p20 

    The article discusses research which revealed the association of long-term use of proton pump inhibitors with increased risk for osteoporosis-related fractures.

  • GI medicines linked to bone fractures.  // Gastrointestinal Nursing;Jun2012, Vol. 10 Issue 5, p7 

    The article reports that the Medicines and Healthcare products Regulatory Agency (MHRA), has issued a warning about long-term use of proton pump inhibitors (PPIs) and gastrointestinal (GI) medicines that are linked to bone fractures.

  • PPIs increase osteoporotic.  // Australian Journal of Pharmacy;May2009, Vol. 90 Issue 1068, p76 

    The article reports on the study that determines the relation between duration of exposure to proton pump inhibitors (PPI) and fractures.

  • Proton pump inhibitors: balancing the benefits and potential fracture risks. Richards, J. Brent; Goltzman, David // CMAJ: Canadian Medical Association Journal;8/12/2008, Vol. 179 Issue 4, p306 

    The article discusses a report published within the issue which suggests that the use of proton pump inhibitors is associated with potential risk of an osteoporotic fracture.

  • Chronic use of PPIs associated with increased risk of hip fracture. Thomas, Jack // Australian Journal of Pharmacy;Jun2012, Vol. 93 Issue 1105, p84 

    The article informs about cohort analysis in order to examine the association between chronic use of proton pump inhibitors (PPIs) and increased risk of hip fracture especially among women with smoking history in Australia. It mentions several PPIS available in Australia which includes...

  • The Relationship Between Proton Pump Inhibitor Adherence and Fracture Risk in the Elderly. Ding, Jian; Heller, Debra; Ahern, Frank; Brown, Theresa // Calcified Tissue International;Jun2014, Vol. 94 Issue 6, p597 

    Studies suggest that long-term use of proton pump inhibitors (PPIs) may be associated with an increased risk of fracture. However, the role of medication adherence in this association is not fully understood. A retrospective cohort study was conducted to examine the relationship between PPI...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics